Aveo Pharmaceuticals, Inc.
AVEODrugs in Pipeline
9
Phase 3 Programs
5
Upcoming Catalysts
2
Next Catalyst
Nov 2026
Market Overview
Stock performance and key metrics
2 upcoming, 0 past
Tivozanib hydrochloride
Carcinoma, Renal Cell
Ficlatuzumab
Metastatic Head-and-neck Squamous-cell Carcinoma
Tivozanib
Renal Cell Carcinoma
tivozanib (AV-951)
Advanced Renal Cell Carcinoma
Sorafenib
Advanced Renal Cell Carcinoma
Tivozanib (1mg)
Advanced Adult Hepatocellular Carcinoma
AV-299 + gefitinib
Carcinoma, Non-Small Cell-Lung
mFOLFOX6
Colorectal Cancer
Everolimus
Gastrointestinal Cancer
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Tivozanib hydrochloride | Phase 3 | Carcinoma, Renal Cell | - | - |
Ficlatuzumab | Phase 3 | Metastatic Head-and-neck Squamous-cell Carcinoma | - | - |
Tivozanib | Phase 3 | Renal Cell Carcinoma | - | - |
tivozanib (AV-951) | Phase 3 | Advanced Renal Cell Carcinoma | - | - |
Sorafenib | Phase 3 | Advanced Renal Cell Carcinoma | - | - |
Tivozanib (1mg) | Phase 2 | Advanced Adult Hepatocellular Carcinoma | - | - |
AV-299 + gefitinib | Phase 2 | Carcinoma, Non-Small Cell-Lung | - | - |
mFOLFOX6 | Phase 2 | Colorectal Cancer | - | - |
Everolimus | Phase 2 | Gastrointestinal Cancer | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Aveo Pharmaceuticals, Inc.'s drug pipeline?→
CatalystAlert tracks 9 drug candidates in Aveo Pharmaceuticals, Inc.'s (AVEO) pipeline across Phase 3, Phase 2. Its lead program is Tivozanib hydrochloride (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Aveo Pharmaceuticals, Inc.'s next FDA catalyst?→
Aveo Pharmaceuticals, Inc.'s (AVEO) next tracked catalyst is a Phase 2 expected November 1, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track AVEO biotech catalysts?→
Add AVEO to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Aveo Pharmaceuticals, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.